Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A weekly rhythm is often easier for the body to integrate with your metabolic processes
It's important to note that high-quality evidence regarding non-diabetic retinopathy eye conditions is still evolving
Our team has reviewed this across hundreds of clients in this space
In 2024, the FDA added a cardiovascular indication after a major outcomes study showed fewer serious heart problems in higher-risk patients with overweight or obesity
Current research focuses on: Ongoing Phase 3 TRIUMPH studies continue evaluating longer observation periods and broader metabolic outcomes
The same FDA document mandates post-marketing trials to demonstrate that the novel agent does not increase cardiovascular risk by more than 30% compared to placebo (henceforth these trials were named cardiovascular outcome trial), if premarketing studies did not already demonstrate this
